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Abstract 
Hepsin is a type-II transmembrane serine protease overexpressed in the majority of human 
prostate cancers. We recently demonstrated that hepsin promotes prostate cancer progression and 
metastasis and thus represents a potential therapeutic target. Here we report the identification of 
novel small-molecule inhibitors of hepsin catalytic activity. We utilized purified human hepsin 
for high-throughput screening of established drug and chemical diversity libraries and identified 
sixteen inhibitory compounds with IC50 values against hepsin ranging from 0.23-2.31μM and 
relative selectivity of up to 86-fold or greater. Two compounds are orally administered drugs 
established for human use. Four compounds attenuated hepsin-dependent pericellular serine 
protease activity in a dose dependent manner with limited or no cytotoxicity to a range of cell 
types. These compounds may be used as leads to develop even more potent and specific inhibitors 
of hepsin to prevent prostate cancer progression and metastasis. 
 
 Introduction 
Prostate cancer is the most common cancer in United States males, with an estimated 
186,320 new cases in 2008, accounting for 25% of cancer incidence and 10% of cancer deaths 
(1). While significant progress has been made in recent years in the understanding molecular 
mechanisms responsible for prostate cancer initiation and progression, therapeutic approaches for 
the treatment of prostate cancer remain limited. While localized prostate tumors are usually 
curable, diagnosis of prostate cancer remains a difficult, inexact process and treatment can result 
in side effects that significantly impact quality of life (2, 3). Metastatic prostate cancer is highly 
resistant to therapeutic intervention and almost uniformly fatal. Therefore, the development of 
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effective novel targeted therapies to inhibit prostate cancer progression and metastasis will have a 
significant impact on prostate cancer mortality. 
Multiple genetic and epigenetic changes take place during human prostate cancer 
initiation and progression (4, 5). Hepsin (HPN) is one of the most upregulated genes in human 
prostate cancer and encodes a type-II serine protease overexpressed in up to 90% of prostate 
tumors with levels often increased >10 fold (6-8). Hepsin is upregulated early in prostate cancer 
initiation and maintained at high levels throughout progression and metastasis. In addition, hepsin 
is also overexpressed in ovarian and renal carcinomas (9, 10).  
Significant evidence indicates that hepsin overexpression plays an important role in the 
promotion of prostate cancer progression and metastasis. Hepsin upregulation in a transgenic 
mouse model of localized prostate cancer promoted progression, causing the transition of 
nonmetastatic cancer into an aggressive carcinoma with metastasis to bone, liver and lung (11). 
The cellular context and level of hepsin expression appear to be important to the phenotype, as 
high levels of hepsin overexpression in a prostate cancer cell line reduces cell proliferation and 
invasion (12). While the molecular mechanisms responsible for hepsin function in prostate cancer 
in vivo are unknown, in vitro evidence indicates that hepsin can activate pro-urokinase 
plasminogen activator (pro-uPA) and pro-hepatocyte growth factor (pro-HGF) (13, 14). 
Activation of the uPA cell-surface serine protease system and HGF-Met scattering pathway may 
be responsible for hepsin promoting metastasis and is consistent with the observed basement 
membrane disruption in mouse prostates overexpressing hepsin (11).  
We sought to identify small molecules that specifically inhibit hepsin catalytic activity 
that may be used as lead compounds to develop targeted drugs to attenuate prostate cancer 
progression. Protease-targeted drugs have proven to be clinically useful for treatment of HIV and 
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hypertension and show potential in the treatment of cancer, obesity, cardiovascular, inflammatory 
and neurodegenerative diseases (15). WX-UK1 is a potent small-molecule inhibitor of uPA 
developed by Wilex and has shown antitumor and antimetastasis activity in a rat breast cancer 
model (16). WX-UK1 has completed phase Ib trials in patients with solid tumors and is currently 
in combination phase I trials with capecitabine in patients with breast cancer and other solid 
tumors.  
We report here the identification of sixteen compounds that potently and selectively 
inhibit hepsin proteolytic activity. Four members are able to attenuate hepsin-dependent 
pericellular proteolytic activity with low or no general cellular toxicity. Two of the sixteen 
compounds are established human-use drugs used for alternate indications with known oral 
dosing strategies. We propose that these newly identified small molecules may be used as lead 
compounds for generation of potent and specific drugs for the treatment of human prostate 
cancer. 
 
Materials and Methods 
Reagents 
The DIVERSet and NINDS II compound libraries and reordered hit compounds from those 
libraries were purchased from Chembridge Corporation and MicroSource Discovery Systems, 
Inc., respectively. The chromogenic peptide pyroGlu-Pro-Arg-pNA (S-2366) was purchased 
through Diapharma Group, Inc. Rabbit anti-human hepsin polyclonal antibody was purchased 
from Cayman Chemical (#100022) and goat-anti-rabbit secondary antibody purchased from 
Jackson ImmunoResearch. Polyclonal rabbit anti-mouse hepsin antiserum was produced against a 
synthetic peptide corresponding to the last 18 amino acids of mouse hepsin. Molecular biology 
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grade DMSO was purchased from Fluka. Trypsin was purchased from ICN (#103140) and 
thrombin was purchased from Sigma (T-3399). 
 
Recombinant Hepsin Expression and Purification  
Recombinant expression and chromatographic purification of human hepsin was performed as 
described previously (17). 
 
Compound Library Screening 
The DIVERSet 10,000 compound and NINDS II 1040 compound libraries were diluted from 20 
and 10μM stock plates in DMSO (respectively) to 20μM 10X solutions in 10% DMSO. Purified 
hepsin was incubated with 2μM compounds in 30mM Tris-HCl, 30mM imidazole, 200mM NaCl 
and 1% DMSO for 30 minutes at room temperature. Chromogenic peptide was added and the 
reactions allowed to proceed for 3 hours. Endpoint absorbance was measured using a VersaMax 
microplate reader (Molecular Devices), corrected for background and residual activity observed 
relative to buffer/solvent controls on each plate.  
 
Hepsin, Trypsin and Thrombin Activity Assays 
Titration of the chromogenic substrate pyroGlu-Pro-Arg-pNA was performed for each enzyme 
and the resulting substrate-velocity data fit with nonlinear regression using GraphPad Prism 4 to 
calculate Vmax and Km. Enzyme assay concentration and observed Km: 0.4nM hepsin, 
Km=170μM, 0.4nM trypsin, Km=78.6μM, thrombin 188mU/mL, Km=106.2μM. Inhibitor activity 
was determined by incubating the individual enzymes with increasing concentrations of 
compounds in the library screen buffer for 30 minutes at room temperature followed by addition 
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of the substrate at the observed Km. The reactions were then followed using a kinetic microplate 
reader and the linear rates of increase in absorbance at 405nm expressed as residual percent 
activity (100% x vi/vo). At least three independent experiments were performed for each enzyme. 
IC50 was calculated by fitting the data to a four-parameter non-linear regression using GraphPad 
Prism 4. The equilibration time dependence of inhibitor potency was determined by incubating 
hepsin with the respective inhibitor at its IC50 value or buffer/solvent alone under the above 
conditions in triplicate. Samples were withdrawn at 30, 60, 120 and 180 minutes and activity 
analyzed by the addition of substrate as above. Data are shown as percent inhibition relative to the 
respective buffer/solvent controls incubated for the same amount of time. The reversibility of 
inhibition was determined using a dilution technique. Hepsin was incubated with the inhibitors at 
their respective IC50 values or buffer control as above for 1 hour at room temperature in triplicate. 
Samples were then diluted with buffer to the additional percentage indicated and activity 




LNCaP, HepG2 and HEK 293FT cells were purchased from ATCC. The spontaneously 
transformed mouse prostate epithelial cell line MP-1 was established by passaging C57/B6 
primary mouse prostate epithelial cells. Cell culture components and suppliers were as follows: 
DMEM, F12 and RPMI base medias (Invitrogen), hydrocortisone (Calbiochem), insulin, T3 and 
cholera toxin (Sigma). Cells were incubated in a humidified (37oC, 5% CO2) incubator and 
passaged at 80% confluence with trypsin/EDTA. Mouse prostate epithelial cells MP-1 were 
maintained in E-media containing: 3:1 DMEM/F12, 37mM sodium bicarbonate, 0.42μg/mL 
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hydrocortisone, 0.89ng/mL cholera toxin, 5.3μg/mL insulin, 5.3μg/mL transferrin, 2.1x10-11M 
T3, pen/strep and L-glutamine with 15% FCS. LNCaP cells were maintained in RPMI 
supplemented with 10% FCS and pen/strep. HepG2 cells were maintained in DMEM 
supplemented with 10% FCS and pen/strep. 293FT cells were maintained in DMEM 
supplemented with 10% FCS, L-glutamine, non-essential amino-acids and pen/strep. 
 
Cell Cytotoxicity Assay 
The general cytotoxicity of the compounds was determined using the CellTiter-Glo Assay from 
Promega. Mouse prostate epithelial, LNCaP and HepG2 cells were seeded in 96-well black 
culture plates at 2x104 cells per well and allowed to attach. Media was aspirated and compounds 
were administered at 20μM in the appropriate media and media with compounds was changed at 
24 and 48 hours. CellTiter-Glo reagent was added to the cells and ATP-coupled luciferase activity 
recorded on a microplate luminometer.  
 
Pericellular Serine Proteolytic Activity Assay 
Plasmids encoding full-length mouse wild-type, active-site S352A mutant hepsin (Genbank: 
NM008281) cDNAs or the empty pLNCX2 vector were transfected into HEK 293FT cells using a 
calcium phosphate protocol. After 3.5hrs, transfect media was replaced with fresh media 
containing 20 μM or 50μM of test compounds or solvent control (0.5% DMSO in media) and 
cells incubated to 24 hours post-transfection. Attached cell monolayers were then washed twice 
with PBS and once with assay buffer (5% CO2 equilibrated phenol-red free DMEM with 1% 
BSA) to remove residual serum proteases/inhibitors. Cells were then incubated in assay buffer 
containing 20 or 50μM compounds for 30 minutes at 37oC. Peptide substrate was then added to a 
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final concentration of 369 µM (observed Km in this system) and the reactions allowed to proceed 
at 37oC. Samples were withdrawn at 20, 40 and 60 minutes, quenched into an equal volume of 
7% acetic acid and absorbance at 405nm measured with a microplate reader. Percent inhibition 
was calculated as residual activity relative to solvent control. Matched samples were used in 




Total protein lysates from transfected, compound treated HEK 293FT cells were separated on 
SDS-PAGE and transferred to Immobilon-P membrane. The membrane was blocked overnight in 
TBST buffer containing: 5% non-fat milk, 2% normal goat serum in 50 mM Tris-HCl, pH 8.0, 
100 mM NaCl, 0.1% Tween-20. The membrane was then incubated in 3% BSA in TBST with 
polyclonal anti-mouse hepsin antibody (1:1000) for two hours at room temperature, washed 3x5 
minutes with TBST and incubated for one hour in 0.1% BSA in TBST containing goat-anti-
rabbit-HRP secondary antibody (1:2000), washed 3x5 minutes in TBST and developed with ECL 
(Pierce). Protein loading was confirmed by stripping the membrane and reprobing with anti-β-
actin antibodies. Expression levels were quantified by densitometry using ImageQuantTL. 
 
Results 
Expression and Purification of the Recombinant Extracellular Region of Hepsin   
The extracellular region of human hepsin consists of residues Ser46 to Leu417 (Genbank: 
BC025716) and contains the catalytic and scavenger receptor cysteine-rich (SRCR) domain. The 
yeast P. pastoris was stably transfected with the hepsin expression construct and the secreted 
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41kD hepsin zymogen was purified from the media using several steps of affinity and ion 
exchange chromatography. During purification to homogeneity, the enzyme spontaneously 
activated as previously reported (17). Protein identity was confirmed by silver stain of SDS-
PAGE separated samples and immunoblotting with anti-hepsin catalytic domain polyclonal 
antibodies (Figure 1A). The purified hepsin was enzymatically active (Figure 1B), cleaving the 
chromogenic serine protease substrate pyroGlu-Pro-Arg-pNA. This proteolytic activity was 
completely inhibited by the broad-spectrum serine protease inhibitor PEFAbloc. 
 
High-Throughput Screening and Characterization of Hit Compounds  
 To identify novel inhibitors of hepsin, we screened the Chembridge DIVERSet 10,000 
compound high-diversity library using an assay based on the cleavage of the chromogenic 
peptide. In addition, the NINDS II library of 1040 compounds was screened to identify hepsin 
inhibitors among established drugs and known bioactive molecules. Screens were performed in a 
96-well format at a final compound concentration of 2µM. To minimize false positives, positions 
1 and 12 of each row contained DMSO/buffer controls. As a measure of reproducibility, the Z’ 
score for this assay was 0.78 (18). Compounds that showed >90% inhibition were individually 
reproduced. Reproduced hits were reordered from the supplier and their inhibitory activity was 
confirmed (Figure 2). IC50 values for these compounds were determined by titration of the 
compounds against kinetic hepsin activity (Figure 3). Relative specificity was determined by 
titration against the serine proteases trypsin and thrombin (Table 1).  
The determined IC50 values for these compounds against hepsin displayed a range of 0.28-
2.31μM. Compounds 1, 3, 7, 9 and 10 are subject to nucleophilic addition and may react with the 
active site serine γO. 2 and 8 share a chlorophenyl substituted thiadiazolurea core, with compound 
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2 displaying higher selectivity. Compounds 5 and 6 share a tetrahydro-3H-cyclopenta[c]quinoline 
core, with 5 displaying both higher potency and selectivity. Compound 3 shares an indole moiety 
with LY178550 (19), the N-H of which forms a hydrogen bond to the γO of the catalytic serine of 
thrombin.  
We observed four total hits from the NINDS II library of drugs and bioactive molecules 
(compounds 13-16). Interestingly, 13 and 14 (meclizine and probucol) are established human-use 
drugs with oral dosing. 15 (anthralin) is a topically administered anti-psoriatic agent. Compound 
16 (2,3-dyhydroxy-6,7-dichloroquinoxaline, an NMDA receptor antagonist) shares a 
tetrasubstituted pyrazine with amiloride, a selective, moderately potent uPA inhibitor (20). 
 
General Cellular Toxicity  
 To provide an estimate of cellular toxicity and the usefulness of the identified inhibitors in 
cell-based systems, we performed general cellular toxicity assays. For this purpose, 20μM 
compounds were incubated with a variety of cell types including the mouse prostate epithelial cell 
line MP-1, the human hepatoma cell line HepG2 and the human prostate cancer cell line LNCaP 
(Figure 4A). Compounds and media were replenished daily for three days. At the end of 
incubation, cell viability was measured using an ATP-luciferase coupled assay. Compounds 1 and 
2 displayed substantial toxicity to LNCaP cells without affecting MP-1 or HepG2 cells. 
Compound 12 was substantially toxic to LNCaP and MP-1 without affecting HepG2. Compound 
15 (a known inhibitor of cellular respiration, metabolism and DNA synthesis (21)) was toxic to 
all cell types, particularly to LNCaP and HepG2 cells. Compounds 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 
14 and 16 displayed limited or no cytotoxicity to these cells at this concentration.  
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Inhibition of Hepsin-Dependent Pericellular Proteolytic Activity  
 To determine whether the identified compounds were able to inhibit cell-based hepsin 
activity, we developed an assay to measure hepsin-dependent pericellular serine-proteolytic 
activity (Figure 4B) (22-26). For this purpose, we utilized HEK 293FT cells expressing full-
length wild-type and catalytically inactive (S352A) mutant mouse hepsin proteins or vector alone. 
Attached cell monolayers were incubated in assay buffer with peptide substrate and the reactions 
allowed to proceed at 37oC. Samples were withdrawn at 20, 40 and 60 minutes, quenched into an 
equal volume of 7% acetic acid and absorbance at 405nm measured with a microplate reader.  
Activity levels were adjusted by altering hepsin expression levels to within the linear range of 
detection. A positive linear rate of activity was observed only for wild-type hepsin-expressing 
cells and was abolished in the presence of the broad spectrum serine protease inhibitor PEFAbloc. 
To determine the potential cytotoxicity of the previously identified hepsin inhibitors in 
this model system, HEK 293FT cells were incubated under identical conditions with 20 and 
50μM of the compounds and cytotoxicity was determined using the ATP-luciferase coupled assay 
as described above (Figure 4C). Compounds 12 and 15 displayed substantial toxicity at 50μM 
and were not further characterized. The remaining compounds at 20 and 50μM final 
concentration of were incubated overnight with hepsin-expressing cells and pericellular 
proteolytic activity was determined in the presence of the compounds, as described above (Figure 
5). As treatment with chemical compounds may alter hepsin expression level (and impact 
pericellular proteolytic activity), hepsin levels in drug-treated cells were determined via 
immunoblotting. Data are displayed as normalized pericellular proteolytic activity/expression 
level relative to vehicle treated wild-type hepsin expressing cells. We found that compounds 3, 4, 
5 and 13 attenuated pericellular proteolytic activity in a dose dependent manner without 
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substantially affecting hepsin expression levels or displaying overt toxicity. Compounds 4 and 5 
offered the most potent inhibition, attenuating activity approximately 60% at 50μM. 3 and 13 
reduced activity approximately 50% and 25% (respectively) at 50μM. To further characterize 
these four compounds, we evaluated the time dependence and reversibility of their biochemical 
inhibition of hepsin. Inhibition of hepsin by compounds 3, 4, 5 and 13 significantly increased 
with extended equilibration time (Figure S1) and this inhibition was not reversible by dilution 
(Figure S2), indicating that these compounds are slow-binding, irreversible inhibitors.  
 
Discussion 
We report here the identification of several small molecules that display potent and 
selective inhibition of the type-II cell-surface serine protease hepsin. Hepsin is overexpressed in 
human prostate, renal and ovarian cancers and significant evidence implicates hepsin as a 
metastasis promoting protease in human prostate cancer. Therefore, specific hepsin inhibitors 
may be useful to attenuate prostate cancer progression and prevent metastasis.  
In this study, we identified sixteen hepsin inhibitors utilizing high-throughput screening of 
small-molecule libraries. To determine the relative selectivity of the newly identified compounds 
for hepsin, we evaluated their inhibitory activity toward the physiologically relevant serine 
proteases trypsin and thrombin. Trypsin is a broad-spectrum serine protease with roles in 
digestion, defense, development and blood coagulation. Thrombin is a chymotrypsin-like serine 
protease that converts fibrinogen to fibrin and has other roles in blood coagulation. Several of the 
compounds identified in this study have substantial selectivity for hepsin, with some of the 
molecules displaying up to 78-fold selectivity toward hepsin versus trypsin and >87-fold 
selectivity toward hepsin versus thrombin. These IC50 values were determined with relatively 
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short incubation times and it is possible that they were reflective of enzyme-inhibitor association 
rate differences. Indeed, compounds 3, 4, 5 and 13 displayed a time-dependent increase in hepsin 
inhibition. In addition, dilution experiments demonstrated that compounds 3, 4, 5 and 13 
irreversibly inhibit hepsin. Compound 3 is subject to nucleophilic addition through 1,4-addition 
and may form a covalent bond with the active site serine γO. The mechanisms that may be 
responsible for the irreversibility of the inhibition by compounds 4, 5, 13 are less clear. In the 
future studies, it will be important to rigorously characterize the inhibitory potency and specificity 
of these compounds under fully equilibrated conditions and to determine their mode of inhibition. 
Cell based efficacy is a significant barrier to the development of inhibitors identified with 
biochemical screens, due to target accessibility, matrix effects and potential non-specific 
cytotoxicity. To determine the ability of these compounds to inhibit cell-based hepsin activity, we 
developed a hepsin-dependent pericellular serine protease activity assay. Four of the identified 
compounds (3, 4, 5 and 13) were able to attenuate pericellular proteolytic activity with limited or 
no cytotoxicity at effective concentrations. Compounds 4 and 5 were among the most potent 
inhibitors of hepsin in the purified biochemical assay, however compounds 3 and 13 were among 
the less potent. This observation, in addition to the increased dosage required to attenuate 
pericellular activity, may be attributable to the presence of albumin in the cell-based system. 
Albumin is known to reversibly bind drugs, reduce their concentration free in solution and alter 
dose-response relationships (27, 28). For example, the non-nucleoside HIV reverse transcriptase 
inhibitor efavirenz (used as part of highly active antiretroviral therapy, HAART) is more than 
99% protein bound in plasma, mainly to albumin (29). Alternatively, it is possible that a portion 
of the pericellular serine protease activity observed upon hepsin overexpression is due to the 
hepsin-mediated activation of other serine proteases, which may take place in the Golgi or 
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endoplasmic reticulum (ER), before proteins are delivered to the cell surface. Therefore, lower 
potency of hepsin inhibitors in the cell-based assay may reflect lower plasma membrane and/or 
Golgi/ER permeability of these compounds. 
Two of the compounds that were identified as non-cytotoxic hepsin inhibitors are orally 
administered human use drugs. Probucol is an antihyperlipidemic agent developed for use in 
coronary artery disease and was one of the most potent and specific in vitro inhibitors of hepsin 
proteolytic activity. Paradoxically, this drug did not reduce pericellular serine protease activity in 
the cell-based assay. It is possible that probucol showed no activity in the cell-based assay due to 
the previously mentioned effects of albumin or its high hydrophobicity. This compound has an 
approximate logP value of 10, is known to be transported almost exclusively by lipoprotein 
vesicles in serum and delivered from these directly into the cell membrane (30, 31). Water-
soluble analogues of probucol (32, 33) have been synthesized and it will be interesting to 
determine whether these compounds show inhibition of hepsin proteolytic activity and function in 
a cell-based assay. Meclizine is an anti-nausea drug and available as an over-the-counter remedy 
for motion sickness. It displayed moderate potency, >10-fold selectivity and was able to attenuate 
hepsin-mediated pericellular proteolytic activity by 30% at 50μM. Presently, meclizine is one of 
the most promising lead compounds and provides a template for hepsin inhibitor optimization via 
medicinal chemistry approaches.  
Prostate cancer develops slowly in the majority of cases; however progression to 
metastasis is highly lethal and can occur rapidly. Treatments to prevent metastasis include radical 
prostatectomy and radiation therapy, both of which carry significant risk to urinary and sexual 
function. Metastatic prostate cancer can be treated with androgen ablation therapy, but almost 
uniformly results in hormone-refractory disease leading to mortality. Effective agents to prevent 
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disease progression would reduce the need for surgical or radiation-based therapies and have a 
significant impact on prostate cancer related mortality. Hepsin inhibitors derived from the lead 
compounds identified here may serve this purpose. 
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1 Chembridge Diverset 5133201 0.28±0.07 3.88±0.85 * 
2 Chembridge Diverset 6066621 0.76±0.26 >20 >20 
3 Chembridge Diverset 6232890 1.93±0.39 7.63±1.51 >20 
4 Chembridge Diverset 6071655 0.35±0.12 19.6±2.7 >20 
5 Chembridge Diverset 5655336 0.57±0.19 31.2±2.0 >20 
6 Chembridge Diverset 5658856 0.98±0.20 10.2±1.5 >20 
7 Chembridge Diverset 5770901 2.31±0.53 13.1±3.0 >20 
8 Chembridge Diverset 6066971 0.72±0.20 1.71±0.21 >20 
9 Chembridge Diverset 6238388 0.98±0.12 20.9±7.5 >20 
10 Chembridge Diverset 6132801 0.93±0.13 7.72±1.10 >20 
11 Chembridge Diverset 6176059 1.31±0.44 2.00±0.33 >20 
12 Chembridge Diverset 6011640 0.33±0.07 3.50±0.67 >20 
13 NINDS II meclizine 2.02±0.37 >20 >20 
14 NINDS II probucol 0.43±0.05 33.5±11.5 >20 
15 NINDS II anthralin 0.23±0.05 1.26±0.30 >20 
16 NINDS II NMDA 
receptor 
antagonist 
0.75±0.09 2.42±0.29 >20 
 
Table 1: Protease inhibitory activities of the compounds identified from library screening. 
*Compound 1 activated thrombin activity, approximately 3-fold at 1μM.  
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Figure Legends 
Figure 1. Characterization of recombinant active hepsin. A, Chromatographically purified 
recombinant human hepsin was produced in P. pastoris and analyzed by silver staining of SDS-
PAGE gel and immunoblotting with anti-hepsin catalytic domain antibodies. B, Purified hepsin is 
proteolytically active and inhibited by a broad-spectrum serine protease inhibitor. 0.4nM purified 
hepsin was incubated at room temperature for 30 minutes in buffer alone (diamonds) or in the 
presence of 4mM PEFAbloc (triangles). The chromogenic serine protease substrate pyroGlu-Pro-
Arg-pNA was then added and enzyme activity observed as a linear increase in absorbance at 
405nm over time.  
 
Figure 2.  Chemical structures of identified hepsin inhibitors. Compounds 1-12 were identified 
from the ChemBridge DIVERSet library. Compounds 13-16 (meclizine, probucol, anthralin and 
2,3-dihydroxy-6,7-dichloroquinoxaline) were identified from the NINDS II library of known 
drugs and bioactives.  
 
Figure 3. Inhibition of hepsin activity by identified compounds. A, Compounds 1-4. B, 
Compounds 5-8. C, Compounds 9-12. D, Compounds 13-16. Purified recombinant hepsin was 
preincubated with indicated compounds for 30 minutes at room temperature. The residual percent 
activity of the enzyme toward the chromogenic substrate was then determined with a kinetic 
microplate reader at 405nm. The data are the mean of three independent experiments. IC50 was 
calculated by four-parameter non-linear regression curve fitting. 
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Figure 4. Cellular toxicity of identified inhibitors and hepsin-dependent pericellular serine 
protease assay. A, The mouse prostate epithelial cell line MP-1 (white bars), human prostate 
cancer cell line LNCaP (grey bars) and human hepatoma cell line HepG2 (black bars) were 
incubated for 72 hours with 20μM indicated compounds in media with 0.5% DMSO. Media and 
drugs were replaced every 24 hours. Cell viability was then determined by an ATP-luciferase 
coupled assay. Puromycin at 5μg/mL and DMSO at 0.5% were used respectively as positive 
control and negative controls. 
B, 293FT cells expressing full-length wild-type, catalytically inactive mouse hepsin mutant or 
empty vector were incubated for 30 minutes in serum-free media containing vehicle alone or the 
broad spectrum serine protease inhibitor PEFAbloc. The chromogenic serine protease substrate 
pyroGlu-Pro-Arg-pNA was then added to the media. The media with cleaved substrate was 
collected at indicated times, quenched and pericellular proteolytic activity observed as absorbance 
at 405nm. Note that only the cells expressing wild-type hepsin, but not the cells expressing 
inactive mutant hepsin, vector alone or wild-type hepsin in the presence of PEFAbloc displayed 
pericellular proteolytic activity. C, Toxicity of the compounds over the course of the pericellular 
protease assay was evaluated by 24-hour treatment of cells with 20 μM (white bars) or 50 μM 
(black bars) compounds relative to vehicle control. Cell viability was then determined by an ATP-
luciferase coupled assay. Puromycin at 5μg/mL was used as a positive control. 
 
Figure 5. Attenuation of hepsin-dependent pericellular protease activity by the identified hepsin 
inhibitors. A, HEK 293FT cells expressing wild-type mouse hepsin, an enzymatically inactive 
mouse hepsin mutant or vector alone were incubated for 24 hours with 20 μM (white bars) or 50 
μM  (grey bars) of the biochemically identified hepsin inhibitors and pericellular proteolytic 
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activity was determined in the presence of the inhibitors as described in Figure 5A. As some of 
the drugs significantly impacted the hepsin expression in HEK 293FT cells, data are displayed as 
pericellular proteolytic activity/expression level relative to that of vehicle treated wild-type hepsin 
expressing cells. B, Immunoblot analysis of hepsin expression levels in HEK 293FT cells 
expressing wild-type and inactive mutant hepsin and treated for 24 hours with indicated drugs. 
Protein loading was controlled via immunoblotting with anti-β-actin antibodies. 
 
Supplemental Materials: 
Figure S1. Equilibration time dependence of hepsin inhibition. Hepsin was incubated with 
indicated compounds (A - compound 3, B - compound 4, C - compound 5, D - compound 13) at 
their respective IC50 values or with buffer/solvent alone. Samples were withdrawn at 30, 60, 120 
and 180 minutes and kinetic enzyme activity analyzed by the addition of substrate. Data are 
shown as percent inhibition relative to the respective buffer/solvent controls, incubated for the 
same amount of time.  
 
Figure S2. Reversibility of hepsin inhibition. Hepsin was incubated with indicated compounds (A 
- compound 3, B - compound 4, C - compound 5, D - compound 13) at their respective IC50 
values or with buffer/solvent control for 1 hour at room temperature. Samples were then diluted 
with buffer to the additional percentage indicated and kinetic enzyme activity analyzed by the 
addition of substrate. Data are shown as percent inhibition relative to the respectively diluted 
buffer controls. 





